Polyomavirus-associated nephropathy (PVAN) is an emerging cause of kidney transplant
failure affecting 1–10% of patients. As uncertainty exists regarding risk factors, diagnosis …

Polyomavirus hominis 1, better known as BK virus (BKV), infects up to 90% of the general
population. However, significant clinical manifestations are rare and limited to individuals …

In the last 10 years, better immunosuppression drugs have decreased the rates of acute
rejection in kidney transplantation but have also led to the emergence of polyomavirus …

Polyomavirus-associated nephropathy (PVAN) is an emerging disease in renal transplant
patients with variable prevalence of 1–10% and graft loss up to 80%. BK virus (BKV) is the …

The human polyomavirus type 1, also called BK virus (BKV), causes polyomavirus‐
associated nephropathy (PVAN) in 1–10% of renal transplant recipients, with graft loss in …

The increasing incidence of BK-associated nephropathy following kidney transplantation
has prompted an examination of strategies for risk reduction and management through …

The incidence of BK virus infection in kidney transplant recipients has increased over recent
decades, coincident with the use of more potent immunosuppression. More importantly …

In the last decade the incidence of BK virus infection has increased in renal transplant
recipients and become an important factor negatively influencing graft outcome. BK virus …

Chronic allograft nephropathy (CAN) remains the Achilles heel of renal transplantation. In
spite of the significant strides achieved in one-year renal allograft survival with newer …

Background: BK polyomavirus (BKV) infection has emerged as an important cause of renal
allograft loss. There is no proven therapy, and much basic clinical information is still lacking …